Search results
Results from the WOW.Com Content Network
The WHO recommendations on which medications should or should not be used to treat Covid-19 are continuously updated. As of July 2022, WHO strongly recommended for non-severe cases nirmatrelvir and ritonavir , and recommended conditionally Molnupiravir , Sotrovimab and Remdesivir .
COVID-19: Shionogi: 3C-like protease inhibitor Entecavir: HIV NRTI 2005 Etravirine (Intelence) [8] HIV NNRTI 2008 Famciclovir: Herpes Zoster: Guanosine analogue 1994 Fomivirsen: AIDS Anti-sense oligonucleotide: Anti-sense FDA-licensed in 1998; Withdrawn in EU (2002), US (2006) Fosamprenavir: HIV ViiV Healthcare: Amprenavir pro-drug: 2003 (FDA ...
In November 2023, the FDA revised the EUA for nirmatrelvir/ritonavir to authorize EUA- or NDA-labeled nirmatrelvir/ritonavir for the treatment of mild-to-moderate COVID‑19 in people aged twelve years of age and older weighing at least 40 kilograms (88 lb), who are at high risk for progression to severe COVID‑19, including hospitalization. [18]
The U.S. Food and Drug Administration has officially approved remdesivir as a treatment for coronavirus, drug manufacturer Gilead Sciences announced Thursday. The Ebola drug was already being used ...
Lipid-lowering agents, also sometimes referred to as hypolipidemic agents, cholesterol-lowering drugs, or antihyperlipidemic agents are a diverse group of pharmaceuticals that are used to lower the level of lipids and lipoproteins, such as cholesterol, in the blood (hyperlipidemia). The American Heart Association recommends the descriptor ...
The test, which on Wednesday received emergency-use authorization from the U.S. Food and Drug Administration, measures the number of neutralizing antibodies that the body's immune system has ...
Antihypertensive agents comprise multiple classes of compounds that are intended to manage hypertension (high blood pressure). Antihypertensive therapy aims to maintain a blood pressure goal of <140/90 mmHg in all patients, as well as to prevent the progression or recurrence of cardiovascular diseases (CVD) in hypertensive patients with established CVD. [2]
AbbVie (ABBV) supports studies evaluating Kaletra for treating COVID-19. Pharma Stock Roundup: ABBV, LLY Coronavirus Product Development Efforts, FDA Updates Skip to main content